AIDS Alert Archives – March 1, 2009
March 1, 2009
View Issues
-
Evidence is mounting for expanded use of HIV rapid testing programs
HIV/AIDS researchers continue to find strong evidence that using rapid HIV testing in settings likely to capture high-risk populations is wise public health policy. -
Recent study shows gaps in use of rapid HIV testing
Investigators recently studied the scope of rapid HIV testing, finding surprisingly limited use in urban hospitals and HIV clinics in the United States.1,2,3 -
Rapid HIV testing underused in jails
For correctional settings in many states the biggest obstacles to implementing an opt-out, rapid HIV testing program are state laws regarding HIV testing and counseling. -
Could health systems, ASOs do rapid testing, prevention in jails?
The combination of rapid HIV testing and brief prevention messages could be a model for use in jails which house a high-risk population. -
Obama's early funding changes suggest HIV epidemic is priority
One of President Barack Obama's first actions as president was to lift the ban on federal funds for international groups that perform abortions or provide information or counseling on abortion. -
HIV/AIDS taking shocking toll on black community
The scourge of HIV/AIDS, which continues to affect the African-American community disproportionately, highlights the importance of a comprehensive strategy to address the U.S. epidemic, federal public health officials recently stressed. -
Abstract & Commentary: Out of Africa: Testing and treating all for eradication
Mathematical models (a case reproduction number/stochastic model and a long-term epidemic dynamics/deterministic transmission model) were used to explore the effect of testing for all people 15 or older for HIV and initiating ARV therapy immediately after diagnosis. -
FDA Notifications
On Jan. 5, 2009, the Food and Drug Administration (FDA) granted approval for generic stavudine capsules, USP, 30 mg and 40 mg, manufactured by Matrix Laboratories, Limited, Hyberdad, India. The application was originally reviewed under expedited review provisions for the President's Emergency Plan for AIDS Relief (PEPFAR) and granted tentative approval in April, 2007. -
CDC preparing fact sheet on ART, risk of transmission
The Centers for Disease Control and Prevention is planning to issue a fact sheet on what is currently known about Antiretroviral Therapy (ART) and sexual transmission in the first quarter of this year, the agency announced.